arrow
返回
R

Robert J. Jones

beatson oncology centre

67H指数
431论文数
2.9W被引数
收录论文 124
发表时间
UK real-world data of radium-223 dichloride in metastatic prostate cancer英国镭-223二氯化物在转移性前列腺癌中的真实世界数据
err2025-12-01
err0
PREAI
errRandhawa, Manreet; Buchanan, Gail; Stratton, Irene M.; Race, Gemma; Challapalli, Amar; Bottomley, David; Logue, John; Sundar, Santhanam; Robinson, Angus; Mclaren, Duncan B.; Stevenson, Robert; O'sullivan, Joe M.; Sweeney, Loretta; Mcgrane, John; Jiang, Xue; Mazhar, Danish; Khoo, Vincent; Mcphail, Neil; Jones, Rob J.
err分享
err收藏
Accuracy of glomerular filtration rate estimates among patients with cancer癌症患者肾小球滤过率估计值的准确性
err2025-09-19
err0
errOAAI
errJennifer S. Lees; Edouard L. Fu; Anne-Laure Faucon; Benjamin MP Elyan; Lesley A. Inker; Andrew S. Levey; Robert J. Jones; Richard H. Wilson; Patrick B. Mark; Juan-Jesus Carrero
err分享
err收藏
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers肿瘤转录组范围表达分类器预测晚期前列腺癌的治疗敏感性
errCell
IF42.5
err2025-08-26
err0
errOAAI
errEmily Grist; Peter Dutey-Magni; Marina A. Parry; Larissa Mendes; Ashwin Sachdeva; James A. Proudfoot; Anis A. Hamid; Mazlina Ismail; Sarah Howlett; Stefanie Friedrich; Lia DePaula Oliveira; Laura Murphy; Christopher Brawley; Oluwademilade Dairo; Sharanpreet Lall; Yang Liu; Daniel Wetterskog; Anna Wingate; Karolina Nowakowska; Leila Zakka; Claire L. Amos; Nafisah B. Atako; Victoria Wang; Hannah L. Rush; Robert J. Jones; Hing Leung; William R. Cross; Silke Gillessen; Chris C. Parker; Teresa Marafioti; Alfonso Urbanucci; Matthew Fittall; Edward M. Schaeffer; Daniel E. Spratt; David Waugh; Thomas Powles; Matthew R. Sydes; Felix Y. Feng; Daniel M. Berney; Mahesh K.B. Parmar; Noel W. Clarke; Elai Davicioni; Tamara L. Lotan; Christopher J. Sweeney; Louise C. Brown; Nicholas D. James; Gerhardt Attard
err分享
err收藏
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialTalazoparib 联合 enzalutamide 治疗 metastatic castration-resistant prostate cancer 男性患者的最终总生存结果:来自随机、安慰剂对照、III期 TALAPRO-2 试验的数据
err2025-07-16
err0
PREAI
errNeeraj Agarwal; Arun A Azad; Joan Carles; André P Fay; Nobuaki Matsubara; Cezary Szczylik; Ugo De Giorgi; Jae Young Joung; Peter C C Fong; Eric Voog; Robert J Jones; Neal D Shore; Fred Saad; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Xun Lin; Cynthia G Healy; Matko Kalac; Dana Kennedy; Karim Fizazi
err分享
err收藏
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialTalazoparib 联合 enzalutamide 治疗 HRR 缺陷型转移性去势抵抗性前列腺癌的男性患者:来自随机、安慰剂对照的 III 期 TALAPRO-2 试验的最终总生存结果
err2025-07-16
err0
PREAI
errKarim Fizazi; Arun A Azad; Nobuaki Matsubara; Joan Carles; André P Fay; Ugo De Giorgi; Jae Young Joung; Peter C C Fong; Eric Voog; Robert J Jones; Neal D Shore; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Dingwei Ye; Xun Lin; Matko Kalac; A Douglas Laird; Dana Kennedy; Neeraj Agarwal
err分享
err收藏
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol二甲双胍用于开始接受雄激素剥夺治疗的转移性前列腺癌患者:一项STAMPEDE平台方案的随机III期试验
err2025-07-07
err0
errOAAI
errSilke Gillessen; Laura Murphy; Nicholas D James; Ashwin Sachdeva; Omar El-Taji; Hoda Abdel-Aty; Amanda I Adler; Claire Amos; Gerhardt Attard; Mohini Varughese; Joanna Gale; Simon Brown; Narayanan Srihari; Alison J Birtle; Mick Brown; Kitty Chan; Simon Chowdhury; William Cross; David P Dearnaley; Omar Din; Peter Dutey-Magni; Duncan C Gilbert; Clare Gilson; Struan Gray; Emily Grist; Uschi Hofmann; Andrew M Hudson; Yatin Jain; Ganesan Jeyasangar; Robert Jones; Mahaz Kayani; Ruth E Langley; Zafar Malik; Malcolm D Mason; David Matheson; Connor McAlpine; Archie Macnair; Robin Millman; Claire Murphy; Minal Padden-Modi; Omi Parikh; Chris Parker; Hannah Rush; Martin Russell; Rajaguru Srinivasan; Santhanam Sundar; Jacob S Tanguay; Fabio Turco; Patrick Williams; Matthew R Sydes; Mahesh K B Parmar; Louise C Brown; Noel W Clarke
err分享
err收藏
Incidence of cancer in people with CKD not requiring kidney replacement therapy: a systematic review and meta-analysis慢性肾脏病患者中不依赖肾脏替代疗法的癌症发病率:一项系统评价和荟萃分析
err2025-03-21
err0
errOAAI
errElyan, Benjamin M. P.; Tan, Beatrix; Lambourg, Emilie; Mcallister, David A.; Jones, Rob J.; Lang, Ninian N.; Mark, Patrick B.; Lees, Jennifer S.; Bell, Samira
err分享
err收藏
Occupational incidence of bladder cancer amongst veteran ammunition technicians of the British Army英军资深弹药技术人员中膀胱癌的职业发病率
err2025-03-01
err0
errOAAI
errCollett, Gareth; Bashford, Tim; Whitehead, Nik J.; Kazimierska, Ewa; Swamy, Gokul Vignesh Kanda; Jones, Robert J.; Van Hemelrijck, Mieke; Bryan, Richard T.
err分享
err收藏
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 studyTalazoparib联合enzalutamide治疗转移性去势抵抗性前列腺癌: 来自随机,安慰剂对照,III期TALAPRO-2研究的安全性分析
err2024-12-01
err0
errOAAI
errAzad, Arun A.; Fizazi, Karim; Matsubara, Nobuaki; Saad, Fred; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Jones, Robert J.; Zschaebitz, Stefanie; Oldenburg, Jan; Shore, Neal D.; Dunshee, Curtis; Carles, Joan; Fay, Andre P.; Lin, Xun; Deannuntis, Liza; Di Santo, Nicola; Zielinski, Michael A.; Agarwal, Neeraj
err分享
err收藏
Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 studytalazoparib和enzalutamide在先前接受过雄激素受体通路抑制剂(ARPI)或多西他赛的mCRPC患者中的疗效:来自TALAPRO-2研究两个队列的事后分析
err2024-09-01
err1
PREAI
errAgarwal, N.; Azad, A. A.; Galceran, J. C.; Fay, A. P.; Matsubara, N.; Szczylik, C.; De Giorgi, U.; Joung, J. Y.; Fong, P. C.; Voog, E.; Jones, R. J.; Shore, N. D.; Dunshee, C.; Zschaebitz, S.; Oldenburg, J.; Lin, X.; Laird, D.; Kalac, M.; Kennedy, D.; Fizazi, K.
err分享
err收藏
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 studyPembrolizumab联合enzalutamide治疗转移性去势抵抗性前列腺癌在enzalutamide治疗进展: 2期主题199研究的队列4和5
err2024-08-12
err1
PREAI
errGraff, Julie N.; Hoimes, Christopher J.; Gerritsen, Winald R.; Vaishampayan, Ulka N.; Elliott, Tony; Hwang, Clara; ten Tije, Albert J.; Omlin, Aurelius; McDermott, Raymond S.; Fradet, Yves; Tagawa, Scott T.; Kilari, Deepak; Ferrario, Cristiano; Uemura, Hiroji; Jones, Robert J.; Fukasawa, Satoshi; Peer, Avivit; Niu, Cuizhen; Poehlein, Christian H.; Qiu, Ping; Suttner, Leah; de Wit, Ronald; Schloss, Charles; de Bono, Johann S.; Antonarakis, Emmanuel S.
err分享
err收藏
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT
err2024-08-01
err0
errOAAI
errCollinson, Fiona; Royle, Kara-Louise; Swain, Jayne; Ralph, Christy; Maraveyas, Anthony; Eisen, Tim; Nathan, Paul; Jones, Robert; Meads, David; Wah, Tze Min; Martin, Adam; Bestall, Janine; Kelly-Morland, Christian; Linsley, Christopher; Oughton, Jamie; Chan, Kevin; Theodoulou, Elisavet; Arias-Pinilla, Gustavo; Kwan, Amy; Daverede, Luis; Handforth, Catherine; Trainor, Sebastian; Salawu, Abdulazeez; McCabe, Christopher; Goh, Vicky; Buckley, David; Hewison, Jenny; Gregory, Walter; Selby, Peter; Brown, Julia; Brown, Janet
err分享
err收藏
Optimising the use of the prostate- specific antigen blood test in asymptomatic men for early prostate cancer detection in primary care: report from a UK clinical consensus优化无症状男性前列腺特异性抗原血液检测在初级保健中早期前列腺癌检测的使用: 来自英国临床共识的报告
err2024-07-22
err1
errOAAI
errHarding, Thomas A.; Martin, Richard M.; Merriel, Samuel W. D.; Jones, Robert; O'Sullivan, Joe M.; Kirby, Mike; Olajide, Oluwabunmi; Norman, Alexander; Bhatt, Jaimin; Hulson, Oliver; Martins, Tanimola; Gnanapragasam, Vincent J.; Aning, Jonathan; Burgess, Meg; Rosario, Derek J.; Pashayan, Nora; Tesfai, Abel; Norori, Natalia; Rylance, Amy; Seggie, Andrew
err分享
err收藏
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancerTALAPRO-2研究结果的简明语言摘要: 塔拉唑帕利加恩扎鲁他胺与安慰剂加恩扎鲁他胺治疗晚期前列腺癌的比较
err2024-07-12
err1
errOAAI
errAgarwal, Neeraj; Azad, Arun A.; Carles, Joan; Fay, Andre P.; Matsubara, Nobuaki; Heinrich, Daniel; Szczylik, Cezary; Giorgi, Ugo De; Joung, Jae Young; Fong, Peter C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschabitz, Stefanie; Oldenburg, Jan; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Zohren, Fabian; Fizazi, Karim
err分享
err收藏
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trialCapivasertib联合恩扎鲁他胺治疗多西他赛和阿比曲酮治疗转移性去势抵抗性前列腺癌: 随机II期RE-AKT试验的结果
err2024-07-01
err1
errOAAI
errRescigno, Pasquale; Porta, Nuria; Finneran, Laura; Riisnaes, Ruth; Figueiredo, Ines; Carreira, Suzanne; Flohr, Penny; Miranda, Susana; Bertan, Claudia; Ferreira, Ana; Crespo, Mateus; Rodrigues, Daniel Nava; Gurel, Bora; Nobes, Jenny; Crabb, Simon; Malik, Zafar; Ralph, Christy; McGovern, Ursula; Hoskin, Peter; Jones, Robert J.; Birtle, Alison; Gale, Joanna; Sankey, Peter; Jain, Suneil; McLaren, Duncan; Chadwick, Eliot; Espinasse, Aude; Hall, Emma; de Bono, Johann
err分享
err收藏
TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
err2024-04-05
err3
PREAI
errPiulats, Josep M.; Azad, Arun A.; Laird, A. Douglas; Matsubara, Nobuaki; Fizazi, Karim; Shore, Neal D.; Karsh, Lawrence; Liu, Glenn; Fay, Andre P.; Carles, Joan; Jones, Robert J.; Voog, Eric; Zschabitz, Stefanie; De Giorgi, Ugo; Yip, Steven M.; Mu, Xinmeng Jasmine; Lin, Xun; Engelsberg, Arne; Agarwal, Neeraj
err分享
err收藏
Identification of a novel agnostic predictive multiomic signature via Elastic Net/Machine Learning in TALAPRO-2 ( TP-2), a phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
err2024-04-05
err0
PREAI
errLiu, Glenn; Mu, Xinmeng Jasmine; Fizazi, Karim; Laird, A. Douglas; Matsubara, Nobuaki; Yip, Steven M.; Pu, Jie; Carles, Joan; Fay, Andre P.; Jones, Robert J.; Zschaebitz, Stefanie; Piulats, Josep M.; Joung, Jae Young; Roh, Whijae; Chelliserry, Jijumon; Di Santo, Nicola; Saul, Michelle; Azad, Arun A.; Agarwal, Neeraj
err分享
err收藏